gvtcx

NHS National Framework for Transition products commencing 1 May 2024

NHS England Published 24 Apr 2024 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£179,392,000
Statuscomplete
Category (CPV) 33600000
Deadline18 Mar 2024
Procedureopen
OCIDocds-h6vhtk-043aa8

Awards (24)

This procurement was awarded to 12 suppliers. Values shown are per-award; the notice total is £179,392,000.

SupplierValueDateStatus
Aspire Pharma Limited shared £7,559,000 15 Apr 2024 active
Aspire Pharma Limited shared · · active
Celix Pharma Ltd. shared £7,559,000 15 Apr 2024 active
Celix Pharma Ltd. shared · · active
Dr.Reddy's Laboratories (UK) Limited shared £7,559,000 15 Apr 2024 active
Dr.Reddy's Laboratories (UK) Limited shared · · active
Glenmark Pharmaceuticals Europe Limited shared £7,559,000 15 Apr 2024 active
Glenmark Pharmaceuticals Europe Limited shared · · active
Immedica Pharma AB shared £7,559,000 15 Apr 2024 active
Immedica Pharma AB shared · · active
Kent Pharma Ltd shared £7,559,000 15 Apr 2024 active
Kent Pharma Ltd shared · · active
LogixX Pharma Ltd shared £7,559,000 15 Apr 2024 active
LogixX Pharma Ltd shared · · active
Mylan shared £7,559,000 15 Apr 2024 active
Mylan shared · · active
Sandoz Ltd shared £7,559,000 15 Apr 2024 active
Sandoz Ltd shared · · active
Selective Supplies Ltd. shared £7,559,000 15 Apr 2024 active
Selective Supplies Ltd. shared · · active
Teva UK Limited shared £7,559,000 15 Apr 2024 active
Teva UK Limited shared · · active
Thornton and Ross Ltd shared £7,559,000 15 Apr 2024 active
Thornton and Ross Ltd shared · · active

description

Project title: NHS National Framework for Transition products commencing 1 May 2024<br/>Offer reference number: CM/TNS/05/2024<br/>Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.<br/>Potential periods of call-offs under the framework agreement:<br/><br/>CM/TNS/05/2024/01<br/>Lot 1 NWLN: 01/05/2024 to 31/01/2025 (9 months)<br/>Lot 2 CESW: 01/05/2024 to 30/09/2025 (17 months)<br/>Lot 3 LSNE: 01/05/2024 to 30/09/2025 (17 months)<br/><br/>CM/TNS/05/2024/02<br/>Lot 1 DNW+DNE+DCE 01/05/2024 to 30/09/2025 (17 months)<br/>Lot 2 DLS+DLN+DSW 01/05/2024 to 30/09/2025 (17 months)<br/><br/>Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

4 notices published against this procurement.

PublishedTypeRegimeNotice
16 Feb 2024 Contract notice (F02) Earlier regulations 005193-2024
16 Feb 2024 Tender (tender) · 5f33fdd2-03b0-44f8-a664-945d0d3b5b9a-724083
24 Apr 2024 Contract award notice (F03) Earlier regulations 013260-2024
24 Apr 2024 Award (award) · 414715d8-13f0-43f1-b262-2414d1189130-743806

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.